Cytokinetics, Incorporated (CYTK)

Market Cap	5.93B
Revenue (ttm)	3.22M
Net Income (ttm)	-576.40M
Shares Out	118.01M
EPS (ttm)	-5.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,097,872
Open	51.57
Previous Close	51.12
Day's Range	48.88 - 51.74
52-Week Range	40.53 - 81.36
Beta	0.83
Analysts	Strong Buy
Price Target	82.00 (+63.15%)
Earnings Date	Feb 27, 2025

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company’s drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Pha...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2004
• Employees: 423
• Stock Exchange: NASDAQ
• Ticker Symbol: CYTK
• Website: https://www.cytokinetics.com

Financial Performance

In 2023, Cytokinetics's revenue was $7.53 million, a decrease of -92.04% compared to the previous year's $94.59 million. Losses were -$526.24 million, 35.3% more than in 2022.

Analyst Forecast

According to 17 analysts, the average rating for CYTK stock is "Strong Buy." The 12-month stock price forecast is $82.0, which is an increase of 63.15% from the latest price.

Price Target

$82.0

(63.15% upside)

Analyst Consensus: Strong Buy